Lidocaine patch for therapy of neuropathic and non-neuropathic pain. A clinical case series of 87 patients

被引:8
|
作者
Kern, K. -U. [1 ]
Kohl, M. [2 ]
Kiefer, R. T. [3 ]
机构
[1] Schmerz & Palliat Zentrum, Facharztzentrum Med, D-65189 Wiesbaden, Germany
[2] Univ Bayreuth, Math Inst, D-95440 Bayreuth, Germany
[3] Univ Tubingen, Abt Anasthesiol & Intens Med, D-72074 Tubingen, Germany
来源
NERVENARZT | 2010年 / 81卷 / 12期
关键词
Lidocain patch; Neuropathic pain; Allodynia; Topical therapy; Local anesthesia; LIGNOCAINE MEDICATED PLASTER; LOW-BACK-PAIN; POSTHERPETIC NEURALGIA; OPEN-LABEL; 5-PERCENT PATCH; DOUBLE-BLIND; QUALITIES; EFFICACY; TRIAL; OSTEOARTHRITIS;
D O I
10.1007/s00115-010-3060-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. Topical lidocaine patches (LP) reduce pain in postherpetic neuralgia and other forms of focal neuropathy. The aim of this study was to determine clinical predictors of therapeutic success. Material and methods. The medical histories of 87 patients with neuropathic (NS) and non-neuropathic pain (NNS) who had received LP as an add-on to their established pain medication were retrospectively analyzed. The variables assessed were gender, age, analgesic co-medication, pain localization, adverse effects and presence of dynamic allodynia. The impact of these variables on the clinical pain-relieving effect (scored on a 5-point scale) was investigated. Results. A total of 24 out of 28 patients with manifest allodynia scored the therapy with LP as beneficial, patients without allodynia (n=59, 67.8%) profited significantly less frequently with only 39% (p<0.001). The probability of profiting from LP therapy in the presence of allodynia was found to be about tenfold higher compared to patients without allodynia (odds ratio 9.14). Of the 87 patients investigated 48 were female (55.2%). Allodynia was considerably more frequent in women (39.6%) compared to men (23.1%) but this was insignificant. Of the female patients 62.5% responded to LP treatment, compared to only 43.6% of men. In more than 60% of cases rated as very good pain relief allodynia was manifest and in non-responders only in less than 10%. The variables age, pain localization and analgesic co-medication were not related with the success of therapy. Discussion. Patients with manifest allodynia profited significantly more frequently from LP therapy and were less frequently non-responders. Female patients showed therapeutic success more often together with a higher rate of allodynia. Conclusions. In the presence of allodynia, in especially of neuropathic origin, LP seems to be an effective and save option for add-on therapy, this being independent from pain localization and age. Gender specific effects however need more systematic investigation.
引用
收藏
页码:1490 / 1497
页数:8
相关论文
共 50 条
  • [1] Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain?
    Fishbain, David A.
    Lewis, John E.
    Cutler, Robert
    Cole, Brandly
    Rosomoff, Hubert L.
    Rosomoff, Rennee S.
    [J]. PAIN MEDICINE, 2008, 9 (02) : 149 - 160
  • [2] Trigeminal Nerve Anatomy in Neuropathic and Non-neuropathic Orofacial Pain Patients
    Wilcox, Sophie L.
    Gustin, Sylvia M.
    Eykman, Elizabeth N.
    Fowler, Gordon
    Peck, Christopher C.
    Murray, Greg M.
    Henderson, Luke A.
    [J]. JOURNAL OF PAIN, 2013, 14 (08): : 865 - 872
  • [3] Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. (vol 8, pg 118, 2007)
    Dworkin, R.
    Jensen, M.
    Gammaitoni, A.
    Olaleye, D.
    Galer, B.
    [J]. JOURNAL OF PAIN, 2007, 8 (06): : 531 - 531
  • [4] Colored Pain Drawing as a Clinical Tool in Differentiating Neuropathic Pain from Non-Neuropathic Pain
    Sehgal, Nalini
    Gordon, Debra B.
    Hetzel, Scott
    Backonja, Miroslav ''Misha''
    [J]. PAIN MEDICINE, 2021, 22 (03) : 596 - 605
  • [5] Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain
    Gagnon, B
    Bruera, E
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (02) : 120 - 125
  • [6] Symptom profiles differ in patients with neuropathic versus non-neuropathic pain
    Dworkin, Robert H.
    Jensen, Mark P.
    Gammaitoni, Arnold R.
    Olaleye, David O.
    Galer, Bradley S.
    [J]. JOURNAL OF PAIN, 2007, 8 (02): : 118 - 126
  • [7] A comparative cost analysis on the use of lidocaine patch 5% and branded and generic gabapentin for treatment of chronic neuropathic and non-neuropathic pain conditions.
    White, RE
    Hawkins, K
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S527 - S527
  • [8] CANCER PATIENTS WITH NEUROPATHIC PAIN SYMPTOMS EXPERIENCE MORE SEVERE PAIN THAN PATIENTS WITH NON-NEUROPATHIC PAIN SYMPTOMS
    Tofthagen, Cindy
    McMillan, Susan C.
    [J]. ONCOLOGY NURSING FORUM, 2008, 35 (06) : 979 - 980
  • [9] Corticomotor excitability is altered in central neuropathic pain compared with non-neuropathic pain or pain-free patients
    Barbosa, Luciana Mendonca
    Valerio, Fernanda
    da Silva, Valquiria Aparecida
    de Lima Rodrigues, Antonia Lilian
    Galhardoni, Ricardo
    Yeng, Lin Tchia
    Rosi Junir, Jefferson
    Conforto, Adriana Bastos
    Lucato, Leandro Tavares
    Teixeira, Manoel Jacobsen
    de Andrade, Daniel Ciampi
    [J]. NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY, 2023, 53 (03):
  • [10] Lidocaine 5% Patch in Localized Neuropathic Pain
    Nair, Abhijit S.
    Mantha, Srinivasa Shyam Prasad
    Azharuddin, Mohammad
    Rayani, Basanth Kumar
    [J]. INDIAN JOURNAL OF PALLIATIVE CARE, 2019, 25 (04) : 594 - +